Published in Clin Orthop Relat Res on January 03, 2008
Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network. PLoS One (2011) 1.78
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 1.13
Association between bone scan index and activities of daily living in patients with advanced non-small cell lung cancer. Support Care Cancer (2017) 1.08
New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med (2014) 1.01
Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev (2009) 1.00
Surgery for skeletal metastases in lung cancer. Acta Orthop (2011) 0.98
Prediction of skeletal-related events in patients with non-small cell lung cancer. Support Care Cancer (2016) 0.96
Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest (2014) 0.94
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis (2011) 0.90
Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics (2012) 0.89
Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Med (2014) 0.88
Prognostic factors for patients with solitary bone metastasis. Int J Clin Oncol (2011) 0.87
Surgical treatment of a patient with lung cancer metastasized to the spine with EGFR mutation: A case report. Int J Surg Case Rep (2012) 0.86
The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. Pathol Oncol Res (2013) 0.82
Long-term survival of a patient with lung cancer metastasis to the spine following surgical treatment combined with radiation and epithelial growth factor receptor inhibitor therapy: A case report. Exp Ther Med (2014) 0.82
Clinicopathologic characteristics and survival of patients with bone metastasis in Yazd, Iran: a cross-sectional retrospective study. Medicine (Baltimore) (2014) 0.81
Discovery of prognostic biomarkers for predicting lung cancer metastasis using microarray and survival data. BMC Bioinformatics (2015) 0.80
Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity? BMC Cancer (2014) 0.80
Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. J Bone Oncol (2014) 0.80
Total en bloc thoracic and lumbar spondylectomy for non-small cell lung cancer with favorable prognostic indicators: is it merely indicated for solitary spinal metastasis? J Korean Neurosurg Soc (2014) 0.78
Lung cancer metastasis presenting as a solitary skull mass. J Surg Case Rep (2016) 0.77
Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol (2013) 0.77
Can surgical management of bone metastases improve quality of life among women with gynecologic cancer? World J Surg Oncol (2014) 0.77
The negative prognostic impact of bone metastasis with a tumor mass. Clinics (Sao Paulo) (2015) 0.76
Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis. J Int Med Res (2016) 0.76
Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer. Onco Targets Ther (2017) 0.75
Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. Oncol Lett (2016) 0.75
Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma. Oncol Lett (2015) 0.75
Metachronous presentation of metastasis from renal cell carcinoma: evaluation and management of spinal metastasis. Evid Based Spine Care J (2010) 0.75
Thoracic Temporal Subtraction Three Dimensional Computed Tomography (3D-CT): Screening for Vertebral Metastases of Primary Lung Cancers. PLoS One (2017) 0.75
A rare case of scapular metastasis from bronchogenic carcinoma with ipsilateral malignant pleural effusion. Lung India (2015) 0.75
Resistance training concomitant to radiotherapy of spinal bone metastases - survival and prognostic factors of a randomized trial. Radiat Oncol (2016) 0.75
Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report. Onco Targets Ther (2015) 0.75
Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients. J Bone Oncol (2015) 0.75
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. PLoS One (2016) 0.75
Metastasis of lung adenocarcinoma to the fifth distal phalange of right hand. BMJ Case Rep (2011) 0.75
Is femoral uptake of Tc99m-methylene diphosphonate on bone scintigraphy in bronchogenic carcinoma an alarming sign: A case report and brief review of literature? Lung India (2014) 0.75
Juxta cortical tibia metastatic deposition in gastric cancer: a case report. Case Rep Med (2012) 0.75
Distribution Features of Skeletal Metastases: A Comparative Study between Pulmonary and Prostate Cancers. PLoS One (2015) 0.75
Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep (2017) 0.75
Factors Associated with Life Expectancy in Patients with Metastatic Spine Disease from Adenocarcinoma of the Lung. Global Spine J (2015) 0.75
Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients. Oncol Lett (2016) 0.75
Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. Int J Clin Oncol (2017) 0.75
Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol (Dordr) (2017) 0.75
Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: An autopsy study. Ann Thorac Med (2017) 0.75
Solitary Skull Metastasis as the First Presentation of a Metachronous Primary Lung Cancer in a Survivor from Pancreatic Cancer. Case Rep Oncol Med (2017) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES. Ann Surg (1940) 26.32
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
Surgical strategy for spinal metastases. Spine (Phila Pa 1976) (2001) 5.81
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63
Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) (1990) 3.97
Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 3.94
Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst (1980) 2.34
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Total en bloc spondylectomy for solitary spinal metastases. Int Orthop (1994) 2.22
Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer (2005) 1.95
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer (2007) 1.85
Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br (2005) 1.80
Bronchial carcinoma and long-term survival. Retrospective study of 433 patients who underwent resection. Thorax (1978) 1.58
Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans. J Nucl Med (1975) 1.51
The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl (2004) 1.45
Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg (2005) 1.37
Pathology of metastatic tumors in bone. Clin Orthop Relat Res (1971) 1.14
Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer (2005) 0.97
[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years]. Nihon Kokyuki Gakkai Zasshi (2006) 0.91
Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res (1999) 0.85
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci (2005) 4.55
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
A plant vacuolar protease, VPE, mediates virus-induced hypersensitive cell death. Science (2004) 2.63
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res (2007) 2.59
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol (2010) 2.55
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol (2013) 2.37
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol (2006) 2.37
Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol (2011) 2.34
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol (2009) 2.33
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol (2002) 2.32
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res (2008) 1.88
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol (2012) 1.85
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol (2009) 1.85
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol (2009) 1.78
How long should small lung lesions of ground-glass opacity be followed? J Thorac Oncol (2013) 1.75
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev (2010) 1.67
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer (2012) 1.67
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol (2007) 1.65
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer (2011) 1.60
Vacuolar processing enzymes are essential for proper processing of seed storage proteins in Arabidopsis thaliana. J Biol Chem (2003) 1.57
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res (2009) 1.52
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn (2006) 1.50
Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. J Immunol (2005) 1.50
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol (2006) 1.50
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer (2004) 1.50
Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol (2006) 1.49
Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer (2004) 1.48
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer (2012) 1.47
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res (2010) 1.44
Fluid drainage and air evacuation characteristics of Blake and conventional drains used after pulmonary resection. Ann Thorac Surg (2009) 1.43
Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res (2008) 1.42
EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol (2005) 1.42
EGFR mutation and response of lung cancer to gefitinib. N Engl J Med (2005) 1.42
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol (2004) 1.42
Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model. Prostate (2013) 1.41
Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene (2004) 1.41
Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion. Ann Thorac Surg (2008) 1.41
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci (2006) 1.40
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis (2004) 1.39
Infectious aortic aneurysms occurring 1 year after bacillus Calmette-Guérin bladder instillation therapy. Int J Urol (2014) 1.38
Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer. J Mol Med (Berl) (2003) 1.37
Vacuolar processing enzyme is essential for mycotoxin-induced cell death in Arabidopsis thaliana. J Biol Chem (2005) 1.37
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol (2008) 1.35
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev (2012) 1.32
LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res (2011) 1.32
Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer (2003) 1.31
Epidermal growth factor receptor mutations in lung cancers. Pathol Int (2007) 1.30
A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst (2007) 1.30
Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene (2002) 1.29
Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci (2007) 1.24
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer (2011) 1.23
A vacuolar processing enzyme, deltaVPE, is involved in seed coat formation at the early stage of seed development. Plant Cell (2005) 1.21
Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer (2008) 1.20
Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis (2007) 1.19
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res (2004) 1.19
Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene (2002) 1.19
Highly oxidized peroxisomes are selectively degraded via autophagy in Arabidopsis. Plant Cell (2013) 1.18
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res (2010) 1.18
EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol (2009) 1.18
The ER body, a novel endoplasmic reticulum-derived structure in Arabidopsis. Plant Cell Physiol (2003) 1.18
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs (2006) 1.17
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther (2012) 1.17
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 1.16
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res (2008) 1.12
Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg (2013) 1.12
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis (2008) 1.11
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol (2006) 1.11
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis (2009) 1.08
Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis (2012) 1.07
Endoplasmic reticulum-resident proteins are constitutively transported to vacuoles for degradation. Plant J (2004) 1.06
Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res (2002) 1.06
Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg (2009) 1.06
The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res (2007) 1.06